Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 24: 1182-1185, 1978;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Therrell, B. L.
Right arrow Articles by Dziuk, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Therrell, B. L., Jr
Right arrow Articles by Dziuk, T. W.

Clinical Chemistry, Vol 24, 1182-1185, Copyright © 1978 by American Association for Clinical Chemistry

Analysis for lead in undiluted whole blood by tantalum ribbon atomic absorption spectrophotometry

BL Therrell Jr, JM Drosche and TW Dziuk

We describe a modified tantalum ribbon atomic absorption procedure for determining lead in undiluted whole blood. An instrumentation Laboratory (I.L.) Model 151 atomic absorption spectrophotometer equipped with an I.L. Model 355 Flameless Sampler was used. The Flameless Sampler was slightly modified to include three-cycle operation instead of the normal two cycles. This modified single-beam system, equipped with background correction, allows 5-microliter specimens of whole blood to be quickly and accurately analyzed. No sample preparation other than vortex mixing is involved and method reliability has been demonstrated during an extended period of successful participation in proficiency testing studies conducted by the Center for Disease Control. This tantalum ribbon methodology has further been demonstrated to be effective both as a primary screening procedure and as a confirmatory procedure, when coupled with erythrocyte protoporphyrin determinations, in screening over 300 000 clients during a three-year period of use in the Early and Periodic Screening, Diagnosis and Treatment (EPSDT) Program in Texas.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1978 by the American Association for Clinical Chemistry.